CX3CR1 and Alzheimer disease: Collectively, our data indicate that partial CX3CR1 deficiency slows progression of AD-like pathology in a transgenic mouse model of the disease and reverses cognitive deficit, by restoring neuronal Aβ-degrading pathways possibly by disrupting CX3CR1-fractalkine interactions.